These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. Kelley M; Ahene AB; Gorovits B; Kamerud J; King LE; McIntosh T; Yang J AAPS J; 2013 Jul; 15(3):646-58. PubMed ID: 23543601 [TBL] [Abstract][Full Text] [Related]
25. Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics. Adamson H; Nicholl A; Tiede C; Tang AA; Davidson A; Curd H; Wignall A; Ford R; Nuttall J; McPherson MJ; Johnson M; Tomlinson DC Biotechniques; 2019 Dec; 67(6):261-269. PubMed ID: 31823668 [TBL] [Abstract][Full Text] [Related]
30. T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020. Jawa V; Terry F; Gokemeijer J; Mitra-Kaushik S; Roberts BJ; Tourdot S; De Groot AS Front Immunol; 2020; 11():1301. PubMed ID: 32695107 [TBL] [Abstract][Full Text] [Related]
31. Bioanalytical Challenges due to Prior Checkpoint Inhibitor Exposure: Interference and Mitigation in Drug Concentration and Immunogenicity Assays. Dengler AF; Weiss R; Truong T; Irvin SC; Gadhia N; Hassanein M; Georgaros C; Taylor JA; Paccaly A; Sumner G; Andisik MD; Torri A; Partridge MA AAPS J; 2021 Oct; 23(6):109. PubMed ID: 34608545 [TBL] [Abstract][Full Text] [Related]
32. Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Martin PL; Bugelski PJ Br J Pharmacol; 2012 Jun; 166(3):806-22. PubMed ID: 22168335 [TBL] [Abstract][Full Text] [Related]
33. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint. Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117 [TBL] [Abstract][Full Text] [Related]
34. Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. Diesendruck Y; Benhar I Drug Resist Updat; 2017 Jan; 30():39-47. PubMed ID: 28363334 [TBL] [Abstract][Full Text] [Related]
35. Current Considerations on Characterization of Immune Response to Multi-Domain Biotherapeutics. Gorovits B; Peng K; Kromminga A BioDrugs; 2020 Feb; 34(1):39-54. PubMed ID: 31641991 [TBL] [Abstract][Full Text] [Related]
36. Understanding preclinical and clinical immunogenicity risks in novel biotherapeutics development. Sauna ZE; Jawa V; Balu-Iyer S; Chirmule N Front Immunol; 2023; 14():1151888. PubMed ID: 37251396 [TBL] [Abstract][Full Text] [Related]
38. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Bugelski PJ; Martin PL Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282 [TBL] [Abstract][Full Text] [Related]
39. Developments in therapy with monoclonal antibodies and related proteins. Shepard HM; Phillips GL; D Thanos C; Feldmann M Clin Med (Lond); 2017 Jun; 17(3):220-232. PubMed ID: 28572223 [TBL] [Abstract][Full Text] [Related]
40. Posttranslational Modifications and the Immunogenicity of Biotherapeutics. Jefferis R J Immunol Res; 2016; 2016():5358272. PubMed ID: 27191002 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]